Authorized Generics Debate Heats Up On Hill, But May Need FTC Study To Boil
Executive Summary
Authorized generics have prompted the reintroduction of several bills and questions about FDA's regulatory actions - but any legislative movement likely depends on a pending Federal Trade Commission report
You may also be interested in...
Brand/Generic Settlement Bill May Need Help From Authorized Generics Limits
Supporters of legislation to curb settlements between brand and generic firms may consider modifying their proposal to include limits on authorized generics to garner more support
Brand/Generic Settlement Bill May Need Help From Authorized Generics Limits
Supporters of legislation to curb settlements between brand and generic firms may consider modifying their proposal to include limits on authorized generics to garner more support
Medicaid AMPs Exclude PBM Discounts Outside Of Mail Order – Final Rules
CMS has been persuaded to exclude pharmacy benefit manager price concessions, other than mail-order, from Medicaid AMPs, because PBMs do not take possession of drug products in most cases nor are their financial transactions easily tracked by manufacturers